Anavex Life Sciences Corp (AVXL)

[Investor2014]

ADL is one aspect of the trial design and there are others that clearly appears to need the totality of evidence from the P2a plus OLE, subgroup analysis, peer review, biomarkers / MRI to hopefully make it through to approval.

Separation of ADAS and SB from placebo was very late in the P2b/3 trial due to tolerability. Final n and lack of clear dose/response 30mg / 50mg another set of aspects that can’t be glossed over.

Overall the P2b/3 trial was not a clear winner, but we are in with perhaps even a good chance from the totality of evidence combined with unmet need.